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Abstract
Background: Chronic kidney disease (CKD) is associated with dyslipidemia, but the role of atherogenic lipid
fractions in CKD progression remains unclear. Here we assess whether baseline plasma levels of lipoprotein(a)
[Lp(a)] and apolipoprotein C-III (apoC-III), causal cardiovascular (CV) risk factors being studied as therapeutic targets,
are associated with decreasing estimated glomerular filtration rate (eGFR) over time.
Methods: In the Penn Diabetes Heart Study (PDHS), a single-center observational cohort of type 2 diabetes patients
without clinical CV disease or pre-existing CKD, we performed linear mixed effects modeling with incremental
multivariable analysis to evaluate the effects of baseline plasma Lp(a) and apoC-III on the slope of eGFR over time
for subjects with longitudinal data (N = 400).
Results: Each two-fold higher plasma Lp(a) level was associated with an additional decline in eGFR by 0.50 mL/
min/year in the fully adjusted model (p < 0.001). Baseline Lp(a) levels greater than the atherogenic cut-point of
30 mg/dL were associated with a decline in eGFR by 2.75 mL/min/year compared to 1.01 mL/min/year in subjects
with baseline Lp(a) less than 30 mg/dL (p < 0.001). Although each two-fold higher apoC-III level was also associated
with statistically significant decline in eGFR over time, as expected the association was attenuated after adjusting for
baseline triglycerides, the key lipid intermediary regulated by apoC-III in circulation.
Conclusions: Elevated baseline plasma Lp(a) levels are associated with a decrease in eGFR over time independent
of race, lipid medication use, and albuminuria, whereas elevated baseline apoC-III levels are associated with eGFR
decline in a triglyceride-dependent fashion.
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Background
Chronic kidney disease (CKD), an independent risk factor
for cardiovascular (CV) disease and CV mortality, is asso-
ciated with dyslipidemia [1–4]. Among other derange-
ments, the circulating lipid profile seen in CKD includes
elevated levels of lipoprotein(a) [Lp(a)], a modified low-
density lipoprotein particle covalently linked to the highly
polymorphic apolipoprotein(a) [apo(a)], a glycoprotein of
genetically-variable protein length that varies widely
among individuals [5–8]. Dyslipidemia in CKD is also
characterized by elevated levels of apolipoprotein C-III
(apoC-III), an exchangeable apolipoprotein on lipoprotein
particles that inhibits lipoprotein lipase, thereby reducing
clearance of very-low-density-lipoproteins (VLDL) and
the triglycerides (TGs) they carry [2, 9–18]. Both Lp(a)
and apoC-III levels have recently been identified as genetic
causal risk factors for CV disease, [5–7, 19–24] but their
role in CKD development and progression remain
unclear.
The purpose of this study was to probe whether baseline
circulating Lp(a) and apoC-III levels are associated with
the development of renal impairment in type 2 diabetes
mellitus (T2DM) patients, a population already at in-
creased risk for adverse CV and renal outcomes [2, 9–18].
Although aberrant concentrations of other lipid fractions
are associated with CKD, we chose to focus on Lp(a) and
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apoC-III due to their already proven causality in CV dis-
ease. Using an observational cohort of T2DM patients
without baseline clinical CV disease or CKD, we examined
the relationship between estimated glomerular filtration
rate (eGFR) decline and baseline concentrations of these
lipoproteins. We hypothesized that higher baseline plasma




The Penn Diabetes Heart Study (PDHS), as previously de-
scribed, [25–29] is an observational cohort of 2118 pa-
tients with T2DM, enrolled and recruited from outpatient
clinics affiliated with the Hospital of the University of
Pennsylvania (HUP) between 2001 and 2011. The Univer-
sity of Pennsylvania (Penn) Institutional Review Board ap-
proved the study protocol, and all subjects gave written
informed consent. Inclusion criteria were: 1) a clinical
diagnosis of T2DM (defined as fasting blood glucose
>126 mg/dl, 2-hour post-prandial glucose >200 mg/dl, or
use of oral hypoglycemic agents/insulin in a subject
greater than age 40 years); 2) age of 35–75 years; and 3) a
negative pregnancy test if female and of child-bearing age.
Exclusion criteria were: 1) history of clinical CV disease
defined by myocardial infarction (MI), documented angio-
graphic coronary artery disease, positive stress test, coron-
ary or peripheral revascularization, stroke, or transient
ischemic attack; 2) insulin use prior to age 35; 3) renal in-
sufficiency defined at the time of recruitment as serum
creatinine greater than 2.5 mg/dL; 4) active infection or
malignancy; and 5) weight more than 300 pounds. For the
current study, subjects were additionally excluded if they
did not have longitudinal serum creatinine data in the
HUP electronic medical records or had baseline eGFR less
than 60 mL/min/1.73 m2, leaving a final sample size of
400 subjects.
Data collection
Study subjects were evaluated at the Clinical and Trans-
lational Research Center (CTRC) at HUP after a 12-
hour fast. They completed a questionnaire regarding
past medical, social, and family history as well as use of
medications. Height, weight, waist and hip circumfer-
ence, and bilateral resting systolic and diastolic blood
pressures were measured. Samples of whole blood and
urine were collected, processed, and stored (at −80 °C).
All lipid data used in the analysis were collected at this
baseline study visit. Complete blood count, basic meta-
bolic panel, hemoglobin A1c, and albuminuria assays
were performed at the clinical laboratories of HUP. TGs
were measured enzymatically, while LDL-C was mea-
sured directly, after ultracentrifugation (β-centrifugation
technique) in a Centers for Disease Control (CDC)
certified lipid laboratory [25, 26, 28]. Lp(a) and apolipo-
proteins were measured by immunoturbidimetric assay
(Wako Chemicals, U.S.A. Inc., Richmond, VA) on a
Hitachi 912 autoanalyzer (Roche Diagnostics, Basel,
Switzerland). Laboratory test results were generated by
personnel blinded to the clinical characteristics of the
study participants.
In this study, hypertension was defined as meeting one
of the following criteria: 1) self-reported history of
hypertension; 2) use of anti-hypertensive medications; 3)
documented systolic blood pressure measurement
greater than 140 mmHg; or 4) documented diastolic
blood pressure measurement greater than 90 mmHg.
eGFR was calculated based on the CKD-EPI equation
[30]. Fasting homeostasis model assessment-estimated
insulin resistance (HOMA-IR) was calculated for a sub-
set of subjects using the following equation: (glucose
[mg/dL] x insulin [μIU/mL] / 405) [31]. Urinary ACR
for each subject, reported in mg/g, was calculated by
dividing spot urine albumin by spot urine creatinine
concentrations. Follow-up clinical laboratory data was
available from 2001–2013, and was collected as part of
routine patient care.
Primary outcomes
Our primary outcomes of interest were the association of
1) baseline Lp(a) concentration and 2) baseline apoC-III
concentration with eGFR slope. As apoC-III has a signifi-
cant role in TG metabolism, [10] we additionally examined
the association of baseline TG concentration with eGFR
slope with and without adjustment for apoC-III concentra-
tions and the converse of apoC-III association with eGFR
slope with and without adjustment for TGs.
Statistical analysis
For descriptive data, distributions are reported as me-
dian and interquartile range (IQR) for continuous vari-
ables and as proportions for categorical variables. Due to
their skewed distributions, for multivariable analysis
Lp(a) and apoC-III were log-transformed (log base 2)
when analyzed as continuous variables. Linear mixed ef-
fects modeling of eGFR with the lipoprotein of interest
was performed in incremental models, and the coeffi-
cient determined from multivariate mixed effects ana-
lysis represented eGFR slope. Model 1 was adjusted for
age, race, gender, and baseline serum creatinine. Model
2 was also adjusted for known risk factors for CKD pro-
gression and for potential lipid-related confounders;
these additional co-variates included body mass index
(BMI), hypertension, use of lipid-lowering medications,
smoking status, alcohol use, and hemoglobin A1c.
Model 3 further adjusted for baseline urinary ACR,
which was examined separately due to its potential role
in affecting lipid metabolism. For additional apoC-III
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analysis, TGs were included in an additional model
(Model 4) as a covariate due to the known biological ef-
fect of apoC-III on TG metabolism [10] i.e., we exam-
ined the impact of TGs as an intermediate effector of
apoC-III on slope of eGFR. With the exception of Model
4, each step in multivariate analysis did not adjust for
other lipid fractions. Additional sensitivity analysis was
performed adjusting for HOMA-IR within a subset of
subjects who had insulin resistance measured. Models
included a random intercept term and an independent
covariance structure. Model goodness-of-fit was assessed
with the Akaike information criterion [32]. Statistical
analyses were performed using STATA version 13.0 soft-
ware (Stata Corps, College Station, TX).
Results
Baseline patient characteristics
Of the 2118 participants in the originally recruited co-
hort, 400 had follow-up creatinine data and were in-
cluded in this analysis. Baseline characteristics of these
400 subjects are presented in Table 1. Except in gender
distribution, these did not differ significantly from the
cohort baseline characteristics as a whole (Table S1).
The study participants are evenly divided between men
(49 %) and women, and 36 % self-identified as Black.
The majority met hypertension criteria (73 %). The me-
dian baseline eGFR was above 90 mL/min/1.73 m2, and
the median urinary ACR was below 6 mg/g (Table 1).
The median baseline Lp(a) concentrations was below the
atherogenic cutpoint of 30 mg/dL, [33] and the median
apoC-III concentration was below 15 mg/dL [10]
(Table 1).
Longitudinal renal measurements
In this cohort sample, mean eGFR decline was 1.49 mL/
min/1.73 m2 per year (95 % CI 1.31, 1.66). Among these
participants, 15 % eventually progressed to CKD with
decline in eGFR to less than 60 mL/min/1.73 m2 within
5 years. Median follow-up time was 4.5 years, and the
median number of follow-up serum creatinine values
per subject was 4.48 laboratory tests.
Association between baseline Lp(a) levels and eGFR
decline
Across all incremental levels of multivariable analysis,
mixed effects modeling demonstrated that baseline Lp(a)
concentrations had a robust association with eGFR decline
(Table 2, Additional file 1: Table S1). After adjustment for
age, race, gender, and baseline serum creatinine (Model 1),
each two-fold increase in baseline plasma Lp(a) level was
associated with a decrease in eGFR by 0.83 mL/min/
1.73 m2 (P < 0.001) per year. A similar trend was seen in
the fully adjusted model, with each two-fold higher plasma
Lp(a) level holding a strong association with a decrease in
eGFR by 0.50 mL/min/1.73 m2 (P < 0.001) per year after
adjusting for demographic factors, baseline serum creatin-
ine, BMI, hypertension, lipid-lowering medications, smok-
ing status, alcohol use, hemoglobin A1c, and urinary ACR
(Model 3). When baseline plasma Lp(a) levels were divided
according to the atherogenic cutpoint of 30 mg/dL, the
Table 1 Patient baseline characteristics
Total (N = 400)









Systolic BP (mmHg) 128 (118, 136)
Diastolic BP (mmHg) 75 (70, 80)
Waist Circumference (in) 42 (38, 46)
BMI (kg/m2) 31.7 (28.0, 36.2)
Glucose (mg/dL) 112 (95, 139)
Hemoglobin A1c (%) 6.7 (6.2, 7.5)
Serum Creatinine (mg/dL) 0.88 (0.70, 1.0)
BUN (mg/dL) 16 (13, 19)
eGFR (CKD-EPI) 91.7 (80.0, 102.1)
Urinary ACR (mg/g) 5.3 (3, 13.5)
Anti-Hypertensive Medications (%)








Lp(a) (mg/dL) 25 (9, 57)
ApoC-III (mg/dL)* 11.4 (8.7, 15.6)
Triglycerides (mg/dL) 105 (79, 156)
LDL-C (mg/dL) 99 (79, 119)
Apolipoprotein B (mg/dL) 80 (69, 94)
Characteristics of cohort at baseline visit. All data reported as median
(interquartile range) unless otherwise specified
BP blood pressure, BMI body mass index, BUN blood urea nitrogen, eGFR
estimated glomerular filtration rate, ACR albumin to creatinine ratio, ARB
angiotensin receptor blocker, CCB calcium channel blocker, Lp(a)
lipoprotein(a), ApoC-III apolipoprotein C-III, LDL-C low density
lipoprotein cholesterol
*N = 336
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degree of eGFR decline was more pronounced in the
>30 mg/dl group than those with Lp(a) <30 mg/dl
(Fig. 1). In fully adjusted analysis, baseline Lp(a) con-
centrations greater than 30 mg/dL were associated with
a decline in eGFR by 2.75 mL/min/1.73 m2 per year
(95 % CI −3.11, −2.39), whereas baseline Lp(a) concen-
trations less than 30 mg/dL were associated with an
eGFR decline of 1.01 mL/min/1.73 m2 (95 % CI −1.21,
−0.81; p for interaction between groups <0.001) (Fig. 1,
Additional file 1: Table S1).
Association between baseline apoC-III levels and eGFR
decline
Adjusting for demographic factors only (Model 1), mixed
effects modeling showed a significant association between
each two-fold higher baseline apoC-III levels and a de-
crease in eGFR by 1.62 mL/min/1.73 m2 (P <0.001) per
year (Table 3, Additional file 1: Table S1). This association,
although mildly attenuated, held even after additionally
adjusting for baseline serum creatinine, BMI, hyperten-
sion, use of lipid-lowering medications, smoking status, al-
cohol use, hemoglobin A1c, and albuminuria (Model 3).
However, the association was markedly attenuated in the
fully adjusted model, which included additional adjust-
ment for baseline TG levels (Model 4) (slope of eGFR de-
cline 0.22, P = 0.26). In a smaller subset of PDHS patients
who had insulin resistance measured, adjustment for
HOMA-IR yielded similar results (slope of eGFR decline
-.17, P = 0.379). Baseline TG levels correlate with baseline
apoC-III levels (Additional file 2: Table S2), consistent
with the concept that these lipid factors may converge in
downstream pathways.
Discussion
In this study of individuals with T2DM, we demonstrate
that baseline plasma Lp(a) levels strongly associate with
eGFR decline and that a significant although more modest
association exists between baseline plasma apoC-III levels
Table 2 Association between two-fold higher baseline plasma
Lp(a) levels and eGFR decline
Analysis eGFR decline, ml/min/1.73 m2 (95 % CI) P-Value
Model 1 −0.83 (−0.97, −0.70) <0.001
Model 2 −0.51 (−0.65, −0.37) <0.001
Model 3 −0.50 (−0.64, −0.36) <0.001
Data represent eGFR change per year for every two-fold higher plasma Lp(a)
concentration, analyzed as a continuous variable. Regression through mixed
effects modeling was performed in incremental models with the
following co-variates
Model 1: Age, gender, race, baseline SCr
Model 2: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering
medications, smoking, alcohol use, hemoglobin A1c
Model 3: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering
medications, smoking, alcohol use, hemoglobin A1c, urinary ACR
*Definition of hypertension includes the use of anti-hypertensive medications
SCr serum creatinine, ACR albumin to creatinine ratio
Fig. 1 eGFR decline by baseline Lp(a) level. Baseline Lp(a) levels were divided into two groups using the atherogenic cutpoint of 30 mg/dL (baseline
Lp(a)≥ 30 N = 181; baseline Lp(a) < 30 N = 219). Regression through mixed effects modeling was performed, and graphical representation of eGFR
changes over time reveals different rates of decline between the two groups. The data depicted reflect the fully adjusted models accounting for the
following co-variates: age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering medications, smoking, alcohol use, hemoglobin A1c, urinary
ACR. Definition of hypertension includes the use of anti-hypertensive medications. Abbreviations: SCr serum creatinine, ACR albumin to creatinine ratio
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and eGFR decrease over time in a TG-dependent fashion.
To our knowledge, this study is among the first to demon-
strate an independent association between baseline circu-
lating Lp(a) levels and eGFR decline in a population
without pre-existing CKD.
Several prior studies have shown that plasma Lp(a)
levels are elevated in CKD patients, [7, 34–36] but the dir-
ection of causality in this trend has been unclear. Past
studies have explored whether Lp(a) elevations in CKD
are due to reduced renal clearance, pointing to differences
in Lp(a) concentrations in the renal arteriovenous circula-
tion [37] as well as reduction in Lp(a) levels after renal
transplant [38]. Although the kidney may play a role in
Lp(a) metabolism, the current study introduces the possi-
bility that circulating Lp(a) may also play a role in renal
impairment. Here we show that in diabetics without base-
line CKD, higher baseline Lp(a) concentrations, including
above the clinical used atherogenic cutpoint of 30 mg/dL,
are strongly associated with decline in eGFR. The eGFR
slope for subjects Lp(a) levels above that cutpoint is more
than twice as steep as the slope for subjects in the lower
Lp(a) group, indicating that higher baseline Lp(a) levels
may accelerate the rate of decline in eGFR that would
otherwise take place due to age and the natural course of
diabetic disease. Because circulating Lp(a) levels do not
vary much over time within healthy individuals, [39] our
results suggest that exposure to higher baseline Lp(a) con-
centrations that would remain unchanged over time may
be a risk factor for eGFR decline. Within the PDHS co-
hort, the strong dose-dependent, temporal relationship
between baseline plasma Lp(a) concentration and negative
eGFR slope is consistent with a potential causal relation-
ship between this lipoprotein risk factor and renal out-
come. However, as has been performed for CVD
outcomes, [5, 6, 20, 40, 41] genetic data and Mendelian
randomization studies will be important to definitively ad-
dress Lp(a) causality in renal disease in humans.
Our findings add valuable insight to the conflicting re-
sults of prior studies examining the relationship between
Lp(a) and GFR. In 2005, Song et al. found in a small co-
hort of 81 individuals with proteinuric diabetic nephrop-
athy that each 10 mg/dL increase in log-transformed
Lp(a) concentration was associated with a 1.4 increased
odds of serum creatinine doubling independent of albu-
minuria, hypertension, and glycemic control [42]. Our
results complement Song et al.’s finding as we further
demonstrate an independent inverse relationship be-
tween Lp(a) concentration and decline renal function in
diabetics without baseline CKD, suggesting that Lp(a) is
not only involved in progression of renal disease but also
possibly the development of GFR impairment.
However, also in 2005, Uhlig et al. found no associ-
ation between Lp(a) and GFR after adjusting for age,
sex, and race in the Modification of Diet in Renal Dis-
ease (MDRD) cohort of 804 participants [35]. The
MDRD study was cross-sectional in nature and focused
on non-diabetic patients with pre-existing moderate
CKD (iothalamate-determined GFR between 13 and
55 mL/min/1.73 m2), a population with different base-
line characteristics from the PDHS cohort of diabetic in-
dividuals without baseline CKD. Considering these
differences in study population, the cross-sectional find-
ings of Uhlig’s study are not directly comparable to our
cohort. Furthermore, over half of the participants in the
MDRD cohort had renal disease of polycystic or glom-
erular origin and thus had other competing pathophysio-
logic mechanisms driving their GFR status.
In a more recent prospective study utilizing the
Chronic Renal Insufficiency Cohort (CRIC), Rahman et
al. also did not find an association between baseline
plasma Lp(a) levels and their endpoints of 50 % decline
in eGFR or progression to ESRD [43]. They did not find
a statistically significant association between Lp(a) and
any degree of eGFR decline in their fully adjusted ana-
lysis, which included the covariates of age, sex, race, dia-
betes status, blood pressure, statin use, smoking,
proteinuria, BMI, and alcohol use. The CRIC study may
suggest that Lp(a) does not predict progression of CKD,
but it does not negate our findings as its baseline popu-
lation characteristics are quite different. Like the MDRD
cohort, CRIC consists of a patient population (both dia-
betics and non-diabetics) with pre-existing moderate to
severe CKD. Our results suggest that Lp(a) plays a role
in the early development of CKD. After CKD has devel-
oped, other more dominant pathologies (such as hyper-
filtration and fibrosis) may drive subsequent eGFR
decline.
Adding to previous knowledge that, like Lp(a), apoC-
III is elevated in CKD, [2, 13, 15, 36, 44] here we report
Table 3 Association between Two-fold Higher Baseline ApoC-III
and eGFR Decline
Analysis eGFR decline, ml/min/1.73 m2 (95 % CI) P-Value
Model 1 −1.62 (−1.93, −1.31) <0.001
Model 2 −0.46 (−0.80, −0.13) 0.007
Model 3 −0.38 (−0.72, −0.05) 0.026
Model 4 −0.22 (−0.60, 0.16) 0.257
Data represent eGFR change per year for every two-fold increase of
log-transformed plasma apoC-III concentration, analyzed as a continuous
variable. Linear regression through mixed effects modeling was performed
in incremental models with the following co-variates
Model 1: Age, gender, race, baseline SCr
Model 2: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering
medications, smoking, alcohol use, hemoglobin A1c
Model 3: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering
medications, smoking, alcohol use, hemoglobin A1c, urinary ACR
Model 4: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering
medications, smoking, alcohol use, hemoglobin A1c, urinary ACR,
triglyceride levels
*Definition of hypertension includes the use of anti-hypertensive medications
SCr serum creatinine, ACR albumin to creatinine ratio
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apoC-III’s association with eGFR decline in a TG-
dependent manner. A prior small study did not find an
association between apoC-III and eGFR slope, but again
it utilized a very different study population consisting of
73 non-diabetic adults who had primary renal disease
due to glomerular disease, polycystic kidney disease, and
interstitial nephritis [15]. Our findings demonstrate a
statistically significant association between baseline
apoC-III levels and eGFR decline that was attenuated
only partly after adjusting for known risk factors of CKD
progression including hemoglobin A1c, a confounder in
both CKD progression and in the lipid metabolism path-
way as hyperglycemia drives TG and VLDL production
[10]. As expected, the association between baseline
apoC-III levels and eGFR slope was then strongly atten-
uated after additional adjustment for baseline TGs; this
result did not change when a subset of subjects with
HOMA-IR data underwent further adjustment for
HOMA-IR. This result is consistent with other studies
showing that TGs are a well-established intermediate of
the apoC-III pathway in causing CVD, [10, 13, 45, 46] as
VLDL-associated apoC-III plays a role in TG lipolysis.
Although insulin resistance, which contributes to in-
creased VLDL secretion and decreased catabolism of TG
rich lipoproteins, would be an expected confounder in
the interplay between apoC-III and TGs in diabetics, ad-
justment for it did not change our results. Further work,
including Mendelian randomization strategies, will be
needed to investigate whether a direct relationship be-
tween VLDL-apoC-III and eGFR decline exists and the
renal mechanisms of this effect, if present.
Conclusions
The current study has several strengths. First, the PDHS
sub-sample with longitudinal eGFR data is similar to the
overall PDHS cohort, is well-characterized and represen-
tative of the broader T2DM population, and thus is po-
tentially generalizable among non-insulin-dependent
diabetics. Second, the study utilizes a cohort without
baseline CKD but with longitudinal follow-up, allowing
for the study of potential development of early CKD.
This complements other study cohorts that focus on in-
dividuals who already have pre-existing CKD. Third, our
study has a unique focus of leveraging CV biomarkers
measured in the PDHS cohort for the study of CKD risk
as well as CVD risk.
Our study also has limitations worth consideration.
Within the larger full PDHS cohort, the sample with longi-
tudinal follow-up is considerably smaller, although the
sample size was large enough to power the multivariable
analysis employed in our study. We only included individ-
uals in our study who continued to receive care at our in-
stitution and who had follow-up serum creatinine values.
This could lead to selection bias, if individuals with higher
levels of apoC-III or Lp(a) were more likely to seek medical
care and, due to greater degrees of observation, more likely
to be detected to have declining eGFR. Also, while geno-
typic data was available for a portion of the larger PDHS
cohort, our final sample size precluded a robust Mendelian
randomization study of the rare or low-frequency LPA and
APOC3 genetic variants and renal outcomes. As studies on
LPA and APOC3 variants have established a causal link be-
tween their respective lipoprotein biomarker and increased
risk of CV disease, [5, 6, 20, 22, 23] leveraging genetic data
as an instrumental variable for CKD risk would more fully
address reverse causation and exclude other confounders.
In addition, prior studies have established an inverse cor-
relation between the size of the apo(a) portion of Lp(a)
and circulating Lp(a) concentrations; [5, 19, 20] but be-
cause the Lp(a) assay used in this current study is not sen-
sitive to apolipoprotein(a) isoform size, we are not able to
establish whether the observed association between base-
line Lp(a) and eGFR decline is isoform dependent. Our
focus is on CKD within a T2DM setting so our findings
cannot be extrapolated to non-T2DM settings. Other study
limitations include the use of eGFR rather than measured
GFR or cystatin-C and recruitment of patients from a sin-
gle geographical area.
In summary, our data show that higher circulating
baseline Lp(a) levels have a robust association with eGFR
decline and that higher baseline apoC-III levels have a
similar, but more modest relationship. These findings
may have implications for whether Lp(a) and apoC-III
are possible therapeutic targets for CKD prevention in
the diabetic population. With emerging Lp(a)-lowering
therapies and APOC3 anti-sense oligonucleotides target-
ing apoC-III on the horizon, [47, 48] further prospective
studies, including Mendelian randomization, of Lp(a)
and apoC-III in larger cohorts are needed to determine
causality and assess the prospects for future clinical
trials.
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